Leijin: Male, born in 1954, China nationality, without permanent residency abroad, ID number:13010219540923 * *, Ph.D. in biochemistry from 1988. Mr. leijin once participated in the national key scientific and technological project "Research on improving the performance of artificial heart valves" (1986- 1990) as the national key scientific and technological project "Development and clinical application of new biological heart valves" (1991-/. 1976- 1978 works as a teaching assistant in the biochemistry department of Jilin medical college. 1978 to 1983 studied in the medical department of Jilin Medical College and obtained a bachelor's degree. 1983- 1984 as a teaching assistant in the biochemical teaching and research section of Shanghai second medical university; 1984 to 1988 as a lecturer in the biochemistry teaching and research section of Hebei medical college; 1988- 1990 studied biochemistry at China College of Medical Sciences, Peking Union Medical College, and obtained a master's degree; 1990- 1995 worked in the valve laboratory of Fuwai Cardiovascular Hospital, Institute of Cardiovascular Diseases, China Academy of Medical Sciences, and was promoted to researcher. 199 1 to 1995 studied biochemistry in China College of Medical Sciences, Peking Union Medical College, and obtained a doctorate; 1995 to 1997, and went to NIH/NIEHS as a visiting researcher. 1997 to 2000, as a senior scientist, served as a senior researcher (senior scientist) at OMRF. From 200 1, he returned to China to start a business and became the chairman of Bairensi Bio. Since 2005, he has served as the chairman of Bairen Medical, and is currently the chairman and general manager of the company, dedicated to the industrialization of artificial biological heart valves. As the project leader, Mr. leijin undertook and completed the National Natural Science Foundation project "Study on Anti-calcification of Artificial Biological Heart Valve", and won the third prize of national technological invention in the project "Development and clinical application of new bovine pericardial valve" from 65438 to 0997. 20 14 "Development and Industrialization of Artificial Heart Valve Ring" won the "Third Prize of Beijing Science and Technology Award" issued by Beijing Municipal Government. 20 14 was selected as the "Innovative Talents Promotion Plan" of the Ministry of Science and Technology; 20 16 was selected as the leading talent of science and technology entrepreneurship in the national "10,000-person plan"; 20 17 "industrialization of surgical biological patch" was awarded the third prize of Beijing science and technology award by Beijing municipal government. In 20 17, he was awarded "Top Ten Most Influential Entrepreneurs" in Beijing's influence selection activity; 20 17 was appointed by the National Cardiovascular Center and the National Cardiovascular Expert Committee as the first member of the Minimally Invasive Cardiovascular Surgery Committee of the National Cardiovascular Expert Committee; 20 18 was hired as the chairman expert by the clinical trial branch of China Medical Device Industry Association. Dr leijin is currently the chairman and general manager of the company.